Mantle cell lymphoma (MCL)
Clinical trials for Mantle cell lymphoma (MCL) explained in plain language.
Never miss a new study
Get alerted when new Mantle cell lymphoma (MCL) trials appear
Sign up with your email to follow new studies for Mantle cell lymphoma (MCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a drug combo shrink Hard-to-Treat lymphoma tumors?
Disease control CompletedThis Phase 2 trial tests whether adding venetoclax to ibrutinib can improve complete responses in Japanese adults with mantle cell lymphoma that has returned or not responded to treatment. Participants take both oral drugs for about 104 weeks, then continue ibrutinib alone until …
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo therapy shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims …
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase 1/2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo shows promise for tough blood cancers in early trial
Disease control CompletedThis early-stage study tested a new drug called PRT2527, alone or with other cancer drugs (zanubrutinib or venetoclax), in 86 people with various blood cancers that had returned or stopped responding to standard treatments. The main goals were to check safety, find the best dose,…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase 1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
CAR-T therapy Follow-Up study shows no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various types of B-cell blood cancers like lymphoma and leukemia. The goal was to check for any new or long-term side effects that might appear months or years after treatme…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase 1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:06 UTC